Marginal zone mucosa-associated lymphoid tissue (MALT) B-cell lymphoma is the most common extranodal non-Hodgkin lymphoma. The t(11;18)(q21;q21) translocation occurs frequently in MALT lymphomas and creates a chimeric NF-jB-activating protein containing the baculoviral IAP repeat (BIR) domains of c-IAP2 (inhibitor of apoptosis protein 2) fused with portions of the MALT1 protein. The BIR1 domain of c-IAP2 interacts directly with TRAF2 (TNFa-receptor-associated factor-2), but its role in NF-jB activation is still unclear. Here, we investigated the role of TRAF2 in c-IAP2/MALT1-induced NF-jB activation. We show the BIR1 domain of c-IAP2 is essential for NF-jB activation, whereas BIR2 and BIR3 domains are not. Studies of c-IAP2/MALT1 BIR1 mutant (E47A/R48A) that fails to activate NF-jB showed loss of TRAF2 binding, but retention of TRAF6 binding, suggesting that interaction of c-IAP2/MALT1 with TRAF6 is insufficient for NF-jB induction. In addition, a dominant-negative TRAF2 mutant or downregulation of TRAF2 achieved by small interfering RNA inhibited NF-jB activation by c-IAP2/MALT1 showing that TRAF2 is indispensable. Comparisons of the bioactivity of intact c-IAP2/MALT1 oncoprotein and BIR1 E47A/R48A c-IAP2/MALT1 mutant that cannot bind TRAF2 in a lymphoid cell line provided evidence that TRAF2 interaction is critical for c-IAP2/MALT1-mediated increases in the NF-jB activity, increased expression of endogenous NF-jB target genes (c-FLIP, TRAF1), and resistance to apoptosis.
Introduction
The inhibitor of apoptosis proteins (IAPs) play pivotal roles in oncogenesis by suppressing apoptosis. The eight known members of the human IAP family are characterized by at least one baculoviral IAP repeat (BIR), a domain known to bind caspases, the proteases responsible for apoptosis. Several IAPs also contain an E2-binding RING finger domain at the carboxy terminus imparting E3 ligase activity, which mediates both autoubiquitination and ubiquitination of various substrates (Salvesen and Duckett, 2002; Eckelman et al., 2006; Schimmer et al., 2006) . Cellular IAP1 and IAP2 were first identified by their association with TNFa-receptorassociated factors À1 and À2 (TRAFs), adapter proteins that associate with various members of the tumor necrosis factor (TNF) receptor family and that mediate activation of protein kinases involved in NF-kB induction and other signal transduction events (Rothe et al., 1995) . The c-IAP1 and c-IAP2 proteins each have three tandem BIR domains, with different protein binding specificities. The interaction of TRAFs with c-IAP1 and c-IAP2 is mediated by their BIR1 domains (Temesgen et al., 2006) .
Mucosal-associated lymphoid tumors (MALTomas) constitute a specific type of B-cell lymphomas arising in extranodal locations, representing 8% of all nonHodgkin's lymphomas. MALTomas are typically associated with chronic inflammation, such as Helicobacter pylori infection (Zucca et al., 2000) , which drives B-cell proliferation. Three recurrent chromosomal translocations are associated with MALT lymphomas, including (a) t(1;14)(p22;q32), which places the BCL-10 gene on chromosome 1p22 adjacent to the immunoglobulin heavy chain gene locus on chromosome 14 (Zhang et al., 1999; Vega and Medeiros, 2001 ), leading to Bcl-10 overexpression; (b) t(14;18)(q32;q21), where the MALT1 gene fuses adjacent to the immunoglobulin heavy chain locus resulting in MALT1 overproduction; (Streubel et al., 2003) and (c) t(11;18)(q21;q21), which fuses the BIR domains of c-IAP2 with portions of the MALT1 protein (Morgan et al., 1999) . Each of these chromosomal translocations results in aberrant NF-kB activity, apparently dysregulating a pathway normally involved in antigen receptor signaling that involves Bcl-10, MALT and other proteins (Lucas et al., 2001) .
In this regard, antigen receptor signaling connects to NF-kB activation through a protein complex that contains CARMA1, Bcl-10 and MALT1 (Thome, 2004) . MALT1 binds TRAF6, which inturn associates with the unusual E2, ubiquitin-conjugating enzyme 13 (Ubc13), which is responsible for non-canonical lysine 63-linked polyubiquitination of IKKg/NEMO, an event that leads to activation of the IkB kinases (IKKs), followed by phosphorylation of IkB-a to target it for canonical lysine 48-linked polyubiquitination and proteasomal degradation, releasing NF-kB. Presumably, the c-IAP2/MALT1 fusion protein deregulates MALT's NF-kB-inducing activity, but the mechanisms involved are unclear. The portions of MALT1 involved in c-IAP2/MALT1 fusions retain the TRAF6 binding site, and thus TRAF6 would be expected to participate. However, c-IAP2 also binds TRAF2 through its first BIR domain, suggesting that TRAF2 could also contribute to NF-kB activation, but conflicting results have been obtained (Varfolomeev et al., 2006; Lucas et al., 2007) .
In this study, we investigated the role of TRAF2 in c-IAP2/MALT1-induced NF-kB activation. By using different c-IAP2/MALT1 fusion proteins and a lymphocytic cell line stably expressing a fusion protein, we provide evidence for a critical requirement for a BIR1-TRAF2 interaction for c-IAP2/MALT1-stimulated NFkB activation. We also link this TRAF2-dependent pathway to the anti-apoptotic activity of the c-IAP2/ MALT1 oncoprotein.
Results
The c-IAP2 and MALT1 portions of the c-IAP2/MALT1 fusion protein operate in cis-but not trans-configuration to induce NF-kB To explore the mechanism by which c-IAP2/MALT fusion proteins induce NF-kB, we first compared NF-kB induction by an intact c-IAP2/MALT1 fusion protein earlier identified in a MALToma (case 1) with fragments of this fusion protein constituting the c-IAP2 segment (comprised of BIR1-3 plus the linker between the BIR3 and the CARD domain) and with the unfused-MALT1 protein (Figure 1a) , asking whether the c-IAP2 and MALT1 contributions to the fusion protein are capable of stimulating NF-kB activation when separated (in trans-versus in cis-configuration). For these experiments, HEK293T cells were transfected with plasmids encoding the full-length or truncated c-IAP2/MALT1 proteins and a NF-kB-luciferase reporter gene plasmid. Neither the c-IAP2 fragment of the fusion protein nor the MALT1 protein induced NF-kB activity when expressed in cells (Figure 1b, bottom) . Moreover, co-expressing the c-IAP2 and MALT1 fragments in trans also failed to induce NF-kB activity, whereas the intact c-IAP2/MALT1 fusion protein in which c-IAP2 and MALT1 maintain a cis-relationship induced robust NF-kB activity. The expression of the full-length fusion protein and fragments was confirmed by immunoblotting (Figure 1b, top) . Therefore we conclude that the c-IAP2 components of the fusion protein must be physically linked to segments of MALT1 to induce NF-kB.
Mutation of residues critical for TRAF2-BIR1 interaction abolishes NF-kB activation by c-IAP2/ MALT1 chimeras We have shown earlier that the BIR1 domain of c-IAP2 is essential for binding to TRAF2 and that glutamic acid 47 and arginine 48 are critical for this binding (Temesgen et al., 2006) . Thus, when these residues are mutated to alanine, the E47A/R48A double-mutant loses its ability to bind TRAF2. Recently, it was shown, and we have confirmed (data not shown) that although the double-point mutant cannot bind TRAF2 the c-IAP2/MALT1 protein still oligomerizes (Lucas et al., 2007) . Using plasmids encoding three different c-IAP2/ MALT1 fusion proteins (cases 1, 2 and 3), we performed DNA transfection dose response studies to explore their ability to induce NF-kB. All of these c-IAP2/MALT1 fusions induced NF-kB activity in a dose-dependent TRAF2-binding BIR1 domain of c-IAP2/MALT1 activates NF-jB JB Garrison et al manner ( Figure 2a) . Next, we examined the ability of the E47A/R48A double mutant version of BIR1 to induce NF-kB activity in the context of the c-IAP2/MALT1 protein. Using the three c-IAP2/MALT1 fusion proteins, we generated ER/AA double mutants at the BIR1 site (mBIR1) and assessed their ability to induce NF-kB activation. Following transient transfection into HEK293T cells, all three mBIR1s show a dramatic reduction in the activation of NF-kB when compared with wild-type (WT) chimeras (Figure 2b , top). The case 2 mBIR1 showed no activation of NF-kB, whereas case 1 and case 3 mBIR1 showed approximately 90 and 60% reductions, respectively (Figure 2b, top) . Immunoblotting confirmed that the WT and mutant versions of the c-IAP2/MALT1 fusion proteins are produced at similar levels (Figure 2b, bottom) . Thus, when the TRAF2 binding site is mutated on BIR1, NF-kB activation is severely limited.
To further verify these findings, we co-expressed case 1 WT versus BIR1 mutant c-IAP2/MALT1 fusion protein and TRAF2 or TRAF6 as epitope-tagged proteins and analysed their ability to interact, as well as their ability to induce NF-kB activity. As expected, the BIR1 ER/AA double mutant of case 1 prevented binding of TRAF2 to the fusion protein ( Figure 3a ). Both WT and mutant c-IAP2/MALT1 fusion proteins bound to TRAF6, verifying a recent report that the c-IAP2/MALT1 fusion protein interacts with TRAF6 through the MALT1 immunoglobulin domains (Noels et al., 2007) (Figure 3a ). Thus, TRAF6 binding is insufficient for NF-kB activation by c-IAP2/MALT1.
WT and MUT c-IAP2/MALT1 proteins both bind to SMAC Although the BIR1 domain of c-IAP2 binds TRAF2, the BIR2 and BIR3 domains bind caspases and SMAC through a crevice that associates with peptidyl motifs on these proteins. Earlier we mutated residues earlier within these crevices to disrupt caspase and SMAC binding (Temesgen et al., 2006) . To compare the roles of BIR1, BIR2 and BIR3 in NF-kB activation by c-IAP2/ MALT1, we compared the ability of c-IAP2/MALT1 (case 1) proteins with BIR1 (E47A/R48A), BIR2 (D219R) and BIR3 (D306R) mutations to induce NF-kB activity when expressed in HEK293T cells by transient transfection. In contrast to BIR1 (E47/R48A), the BIR2 (D49R) and BIR3 (D306R) mutants retained NF-kB-inducing activity, suggesting that caspase and SMAC binding is unrelated to the ability of the c-IAP2/MALT1 fusion protein to induce NF-kB (Figure 3b, bottom) . Immunoblotting confirmed that the c-IAP2/MALT1 BIR1 (E47A/R48A), BIR2 (D219R) and BIR3 (D306R) mutants were expressed at comparable levels ( Figure 3b ). Then we extended these studies, comparing the activity of c-IAP2/MALT1 (case 1) fusion proteins in which BIR1, BIR2 or BIR3 was deleted entirely. Again, whereas DBIR1 failed to induce increases in NF-kB activity, the DBIR2 and DBIR3 mutants retain NF-kB-inducing activity, though DBIR2 was somewhat reduced in NF-kB-inducing activity and DBIR3 was significantly increased (Figure 3c , bottom). Therefore we conclude that the TRAF2-binding BIR1 domain of c-IAP2/MALT1 is essential for NF-kB-inducing activity.
TRAF2 is required for NF-kB activation by c-IAP2/ MALT1 fusion protein We used two complementary approaches to interrogate the role of TRAF2 in NF-kB induction by c-IAP2/ MALT1 fusion proteins. First, we co-transfected c-IAP2/MALT1 with a dominant-negative mutant of TRAF2-binding BIR1 domain of c-IAP2/MALT1 activates NF-jB JB Garrison et al TRAF2 in which the RING domain was deleted, thus alleviating Ubc13 dependent ubiquitination (Habelhah et al., 2004) . Increasing amounts of DRING TRAF2 co-transfected with c-IAP2/MALT1 reduced NF-kB activation in a dose-dependent manner (Figure 4a ). In contrast, co-expression of c-IAP2/MALT1 with full-length TRAF2 resulted in increased NF-kB activity (Figure 4b) . Second, as dominant-negative proteins can have non-physiological effects, we also used genesilencing technology to assess the role of TRAF2 in NF-kB activation by c-IAP2/MALT1. To this end, we used vectors encoding short hairpin RNAs (shRNA) Lysates were normalized for protein content (20 mg) and blots were probed with antibodies recognizing a-Myc, TRAF2, or b-actin.
TRAF2-binding BIR1 domain of c-IAP2/MALT1 activates NF-jB JB Garrison et al
targeting TRAF2 on RNA at two different sites (shRNA1 and 2) and introduced the reagents (or scrambled control shRNA) into HEK293T epithelial and Jurkat lymphoid cells. In both HEK293T and Jurkat cells, TRAF2-targeting shRNAs reduced the levels of endogenous TRAF2 proteins when compared with empty vector and scrambled shRNA, with shRNA1 more potent than shRNA2 (Figure 4c, top) . Immunoblot analysis showed no off-target activity from these shRNAs against TRAF6 (data not shown), further confirming selectivity. In cells in which TRAF2 protein levels were reduced by shRNA, NF-kB induction by c-IAP2/MALT1 was significantly reduced (Figure 4c , bottom). We conclude therefore that TRAF2 is required for NF-kB induction by c-IAP2/MALT1 in both epithelial (HEK293T) and lymphoid (Jurkat) cells.
TRAF2-binding c-IAP2/MALT1 oncoprotein induces expression of anti-apoptotic genes and confers protection from cytokine-induced cell death
We sought to explore the physiological significance of TRAF2 interaction with c-IAP2/MALT1 by comparing the cellular effects of TRAF2-binding (WT) c-IAP2/ MALT1 with TRAF2-non-binding BIR1 (E47A/R48A) c-IAP2/MALT1 (MUT) when stably expressed in Jurkat cells. Accordingly, electroporation followed by G418 selection was used to generate stable transfectants, as well as 'empty' vector controls (N). We first compared several clones containing either the WT or MUT fusion protein. Figure 5a shows that of the three WT clones tested, WT5 had the strongest NF-kB inducing capacity when compared with normal Jurkat cells. The ability of the mutant c-IAP2/MALT1 protein to induce NF-kB activity was absent in the four MUT cells assayed (Figure 5a , bottom). The stably transfected cells were further analysed for their ability to induce binding of NF-kB transcription factors to their respective DNA sequences. The strongest NF-kB DNA binding activity was observed in WT5, followed by WT2 and WT3 (Figure 5b) , correlating with the NF-kB reporter gene studies. All MUT clones showed only background levels of NF-kB binding activity when compared with N cells (Figure 5b ). Immunoblotting confirmed equivalent expression of the WT and MUT fusion proteins in the stably transfected Jurkat cells (Figure 5a, top) . For further experiments, the WT5 and M4 clones were utilized and are henceforth referred to as WT and MUT. We next utilized our TRAF2-targeting shRNA vector to confirm that the elevated NF-kB activation seen in the Jurkat cells expressing WT c-IAP2/MALT1 is TRAF2-dependent. Indeed, TRAF2-targeting shRNA markedly reduced NF-kB activity in Jurkat cells expressing WT c-IAP2/MALT1, whereas scrambled control shRNA did not (Figure 6a, middle) . Immunoblotting confirmed that the WT and MUT versions of c-IAP2/MALT1 were expressed in Jurkat lymphoid cells (Figure 6a, top) .
Using the stably expressing WT and MUT c-IAP2/ MALT1 Jurkat cells as a model of dysregulated NF-kB activation as seen in MALT lymphomas, we next explored effects on selected NF-kB target genes. Immunoblot analysis of NF-kB-regulated proteins showed upregulation of the levels of TRAF1 and c-FLIP in the WT, but not the MUT or N cells (Figure 6b) . Interestingly, the MUT Jurkat cells expressing the TRAF2-non-binding c-IAP2/MALT1 (E47A/ R48A) showed reduced levels of c-FLIP when compared with N cells (Figure 6b) , implying a dominant-negative inhibitory effect on endogenous NF-kB-inducing mechanisms. In contrast to TRAF1 and c-FLIP, levels of the NF-kB-inducible adhesion protein, ICAM, were not significantly different in the N, WT and MUT Jurkat cells, as determined by flow cytometry (not shown).
Next, we examined sensitivity of stably transfected Jurkat cells to cell death induced by TNFa, TRAIL and Fas, which are known to stimulate apoptosis through mechanisms that are suppressed by c-FLIP (Kreuz et al., 2001; Micheau and Tschopp, 2003) . Treatment with the combination of TNFa and cycloheximide induced robust cytotoxicity in cultures of N and c-IAP2/MALT1 (E47A/R48A) (MUT) cells, but not c-IAP2/MALT1 (WT) cells (Figure 6c ). Stimulating Fas with agonistic monoclonal antibody, CH11, induced modest cytotoxicity in cultures of N Jurkat cells, which was significantly greater in Jurkat cells expressing c-IAP2/MALT1 (E47A/R48A) mutant (MUT). In contrast, Jurkat cells expressing WT c-IAP2/MALT1 were resistant to Fasinduced apoptosis (Figure 6c ). Jurkat cells expressing c-IAP2/MALT1 (WT) oncoprotein were also more resistant to TRAIL-induced apoptosis (Figure 6c ). We conclude that TRAF2 binding by c-IAP2/MALT1 is required for anti-apoptotic activity.
Discussion
The primary mechanisms of apoptosis suppression by IAPs appear to be through direct inhibition of caspases-3, -7 and, -9. In addition, through their BIR domains the IAPs interact with several signaling modulators. The t(11;18)(q21;q21) translocation is the most common cytogenetic abnormality observed in MALT lymphomas, creating the c-IAP2/MALT1 oncoprotein. This fusion protein is capable of constitutively activating NF-kB, possibly supporting oncogenic progression by promoting survival and proliferation of B-cells. The BIR1 domain of c-IAP2 is critical for NF-kB activation by the fusion protein, although the role of TRAF2 in this signaling pathway has been the subject of debate. A recent report suggests that TRAF2 does not play a role in the ability of c-IAP2/MALT1 to induce NF-kB, and that the binding of TRAF2 simply plays a role in oligomerization (Varfolomeev et al., 2006) . In contrast, others have found TRAF2 to be necessary for effective NF-kB activation (Lucas et al., 2007) . Therefore, we sought to address this issue using alternative and complementary approaches. Using a dominant-negative mutant of TRAF2 that lacks the RING domain, as well as by downregulating endogenous levels of TRAF2 protein using shRNA, we show an absolute requirement for TRAF2 for NF-kB activation by c-IAP2/MALT1. In addition, we observed that introducing the E47A/ R48A mutations into c-IAP2/MALT1, which we showed earlier eliminate TRAF2 binding by both c-IAP1 and c-IAP2 (Temesgen et al., 2006) , resulted in loss of NF-kB induction and loss of TRAF2 association, whereas still preserving binding to TRAF6. Thus, we conclude that TRAF2 is required for NF-kB induction by c-IAP2/MALT1.
Recent reports have suggested that c-IAP2/MALT1 might stimulate NF-kB activation through TRAF6 (Zhou et al., 2004 (Zhou et al., , 2005 . In this regard, a novel TRAF6 binding site has been reported in the second immunoglobulin domain of MALT1 (Noels et al., 2007) . In agreement with others (Lucas et al., 2007) , we observed that DRING TRAF6 dominant-negative also suppresses NF-kB signaling by c-IAP2/MALT1 (not shown). Thus, it is likely that both TRAF2 and TRAF6 are required for c-IAP2/MALT1 activity, though further analysis is needed to confirm this hypothesis.
Given that TRAF6 binds to the C-terminal region of MALT1 and given that over-expression of WT MALT1 failed to induce NF-kB, it appears that the fusion of the BIRs of c-IAP2 with the TRAF6-binding region of MALT1 imparts functions that confer NF-kB-inducing activity. Our comparisons of the effects of expressing the c-IAP2 fusion region in cis versus trans with MALT1 confirm that the fusion event produced by t(11;14) translocations is required for activating this oncoprotein. One functionality previously ascribed to the fusion protein that is not found in either c-IAP2 or MALT1 individually its ability to oligomerize (Lucas et al., 2007) . In this sense, the c-IAP2/MALT fusion protein may mimic physiological mechanisms for TRAF activation, which normally occurs when these E3 ligases are recruited to clustered TNF-receptor and Toll-like receptor complexes (Rothe et al., 1994; Silverman and Maniatis, 2001; Akira and Takeda, 2004) .
NF-kB family transcription factors are known to induce expression of numerous apoptosis-regulating genes (Chu et al., 1997; Kreuz et al., 2001; Micheau et al., 2001) . Expression of WT c-IAP2/MALT1 oncoprotein in Jurkat lymphoid leukemia cells resulted in elevated expression c-FLIP, a documented NF-kB target gene with anti-apoptotic activity. In contrast, c-IAP2/MALT1 (E47A/R48A) mutant protein did not induce NF-kB activity or c-FLIP expression in Jurkat cells, thus confirming the TRAF2 dependence of this phenotype. Furthermore, these TRAF2-dependent phenotypes were correlated with resistance to apoptosis induced by TNFa and Fas. Altogether, these observations identify interaction with TRAF2 as a critical downstream effector of the c-IAP2/MALT oncoprotein and suggest that agents disrupting this interaction may have utility as therapeutics for MALTomas.
Materials and methods

Plasmids, mutagenesis
Deletions and site-specific mutations were introduced by PCR using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). All mutations were confirmed by DNA sequencing. The resulting cDNAs were subcloned into the pcDNA3 expression vector (Invitrogen, Carlsbad, CA, USA).
Three MALT chimeras were obtained, which vary in the breakpoints for c-IAP2 and MALT1 (Akagi et al., 1999; Dierlamm et al., 1999) . Chimera-1 (case 1) contains BIR1-3 of c-IAP2 fused to the caspase-like domains of MALT1. Chimera-2 (case 2) contains the BIR1-3 region of c-IAP2 fused to the immunoglobulin-like (IGL) 1, IGL2 and caspaselike domains of MALT1. Chimera-3 (case 3) contains BIR1-3 of c-IAP2 fused to IGL2, and caspase-like domains of MALT1. These c-IAP2/MALT1 fusion proteins were expressed from pcDNA3 plasmids with FLAG or Myc tags.
Cell culture and transfections Cells were grown in either Dulbecco's modified Eagle's medium (HEK293T) or RPMI 1640 (Jurkat) media supplemented with 10% fetal bovine serum, L-glutamine and penicillin/streptomycin. Transfections were performed using Lipofectamine2000 reagent (Invitrogen) in Opti-MEMreduced serum medium (Invitrogen). The Lipofectamine transfection mix was replaced with fresh medium after 4 h.
For stable cell lines, Jurkat cells were electroporated using the Amaxa Biosystems (Amaxa, Gaithersburg, MD, USA) Cell Line Nucleofector Kit V using the reagents and following the recommendations by the manufacturer (program C-016). Electroporated cells were continuously subjected to 1 mg per ml of G418 selection medium 48 h post-transfection. Single cell clones were derived by limiting dilutions in 96-well plates. Colony growth was followed by microscopy and cells were transferred from the highest dilution wells to 12-well culture plates, after which clones were expanded and expression of the transgene was assessed by PCR and immunoblotting. The stable Jurkat cell clones were routinely re-checked for continuing expression of the transgenes.
Short hairpin RNAs predesigned and targeted against TRAF2 were purchased from SuperArray (SuperArray, Fredrick, MD, USA) and gene silencing was carried out according to the manufacturer's protocol. Briefly, HEK293T and Jurkat cells were transfected with one of two shRNAs targeted against TRAF2 or a scrambled version using Lipofectamine2000 (Invitrogen). At 24 h post-transfection, the cell medium was replaced and the NF-kB reporter assays were performed as described below.
